Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement

by rvvadmin | Aug 11, 2025 | 2025

TORONTO, Aug. 11, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed...

Revive Therapeutics Announces Proposed Private Placement and Debt Settlement

by rvvadmin | Jul 30, 2025 | 2025

TORONTO, July 30, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it is proposing...

Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study

by rvvadmin | Jul 9, 2025 | 2025

TORONTO, July 08, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialized life sciences company dedicated to the research and development of therapeutics for infectious diseases and medical...

Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity

by rvvadmin | Jun 26, 2025 | 2025

TORONTO, June 26, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical...

Revive Therapeutics Advances with Next-Generation Bucillamine Development

by rvvadmin | Jun 4, 2025 | 2025

TORONTO, June 04, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, is pleased to announce the...